Sector News

Actelion CEO says has received no takeover approaches

October 21, 2014
Life sciences
(Reuters) – Actelion has received no takeover bids from interested parties, the company’s chief executive said on Tuesday.
 
Analysts have in the past touted Actelion as a potential takeover target, since its healthy pipeline drugs to treat pulmonary arterial hypertension could draw U.S. bidders seeking to lower their tax bill by moving their tax base to Switzerland, a tactic known as inversion.
 
But last month’s rule changes by the U.S. Treasury Department aimed at curtailing such deals has prompted several pharmaceutical companies, including AbbVie, to ditch original M&A plans.
 
Asked by Reuters whether Actelion has been approached by any interested parties, the company’s Chief Executive Jean-Paul Clozel said, “No.”
 
Speaking after Actelion published third-quarter results that beat expectations, Clozel said the biotech firm wanted to increase shareholder returns and grow ahead of the market at the same time.
 
(Reporting by Caroline Copley)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).